{"id":1006965,"date":"2026-09-30T07:26:27","date_gmt":"2026-09-30T11:26:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/"},"modified":"2026-09-30T07:26:27","modified_gmt":"2026-09-30T11:26:27","slug":"ocugen-to-participate-in-upcoming-scientific-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/","title":{"rendered":"Ocugen to Participate in Upcoming Scientific Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>MALVERN, Pa., Sept.  30, 2026  (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences.<\/p>\n<p>\n        <strong><br \/>\n          <u>Euretina Innovation Spotlight (EIS) 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Location: <\/strong>VIECON, Vienna, Austria<br \/><strong>Date:<\/strong> Wednesday, September 30, 2026<br \/><strong>Time:<\/strong> 2:34 p.m. CEST<br \/><strong>Format:<\/strong> Company presentation<br \/><strong>Title:<\/strong> Ocugen Company Overview<br \/><strong>Presenter:<\/strong> Abhi Gupta, Executive Vice President, Commercial and Business Development, Ocugen<\/p>\n<p>\n        <strong><br \/>\n          <u>26<sup>th<\/sup><\/u><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <u>\u00a0Euretina Congress 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Location: <\/strong>VIECON, Vienna, Austria<br \/><strong>Date:<\/strong> Thursday, October 1, 2026<br \/><strong>Time:<\/strong> 1:00\u20131:06 p.m. CEST<br \/><strong>Format:<\/strong> Podium presentation<br \/><strong>Title:<\/strong> Subretinal RORA-Based Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Phase 1\/2 Safety and Quantitative Lesion Analysis<br \/><strong>Presenter:<\/strong> Jay Chhablani, MD<\/p>\n<p>\n        <strong>Date:<\/strong> October 1\u20134, 2026<br \/><strong>Format:<\/strong> On-Demand ePoster<br \/><strong>Title:<\/strong> Clinical Trial Results from GARDian1 Trial &#8211; A Novel Modifier Subretinal Gene Therapy for Stargardt Disease<br \/><strong>Presenter:<\/strong> Benjamin Bakall, MD, PhD<\/p>\n<p>\n        <strong><br \/>\n          <u>American Academy of Ophthalmology (AAO) Annual Meeting 2026<\/u><br \/>\n        <\/strong><br \/>\n        <br \/>\n        <strong>Location: <\/strong>Ernest N. Morial Convention Center, New Orleans, LA<br \/><strong>Date: <\/strong>Friday, October 9, 2026<br \/><strong>Time: <\/strong>5:05\u20135:10 p.m. CST<br \/><strong>Format: <\/strong>Podium presentation<br \/><strong>Title: <\/strong>OCU410, a Modifier Gene Therapy for GA: Twelve-Month Topline Safety and Efficacy Results from the Phase 2 ArMaDa Trial<br \/><strong>Presenter: <\/strong>Raj K. Maturi, MD<\/p>\n<p>\n        <strong>Date: <\/strong>Sunday, October 11, 2026<br \/><strong>Time: <\/strong>12:06\u201312:13 p.m. CST <br \/><strong>Format: <\/strong>Podium presentation<br \/><strong>Title: <\/strong>OCU410, a Modifier Gene Therapy for GA: Twelve-Month Safety and Efficacy Results from the Phase 2 ArMaDa Trial<br \/><strong>Presenter: <\/strong>Syed Mahmood Shah, MD<\/p>\n<p>\n        <strong>Date: <\/strong>October 9\u201312, 2026 <br \/><strong>Format: <\/strong>On-Demand ePoster<br \/><strong>Title: <\/strong>Phase 1 Dose-Escalation Trial (GARDian1) of OCU410ST in Early to Advanced Stargardt Disease: Safety and Efficacy Results<br \/><strong>Presenter: <\/strong>Ramiro S. Maldonado, MD<\/p>\n<p>\n        <strong>Date: <\/strong>October 9\u201312, 2026<br \/><strong>Format: <\/strong>On-Demand ePoster<br \/><strong>Title: <\/strong>Safety and Efficacy of OCU400 in Retinitis Pigmentosa: Durable Visual Function Benefit Across Multiple Mutations at 3 Years<br \/><strong>Presenter: <\/strong>Benjamin Bakall, MD, PhD<\/p>\n<p>\n        <strong>About Ocugen, Inc.<\/strong><br \/>\n        <br \/>Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company\u2019s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen\u2019s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mtJ5Upy1V2waBWxDeuKgtDJksa8LPcNIOCH1Bh-LXt55djtDbs3b0Kxd00eBwSTMCVhejHrdBFRxP8Kry1JuXA==\" rel=\"nofollow\" target=\"_blank\">www.ocugen.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3zC1SRQ-bmmaRpmezGUuHlbRadXXu1jYZKnVLGi9S4flXv2bHm9r8M_zK75-8_wBqt1JRI8_MQTin2izYCQ-RK6o8GBcHzUBKpEUYAef_pw=\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=846QmXX9E_wQGpqdRpLtsIVcFfF5VnxpyJQfU29wpyWcRGis9Xsjc_zmiJZSbxuD\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p><strong>Cautionary Note on Forward-Looking Statements<\/strong><br \/>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as \u201cpredicts,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cproposed,\u201d \u201ccontinue,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled \u201cRisk Factors\u201d in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.<\/p>\n<p>\n        <strong>Contacts<\/strong>:<\/p>\n<p>Investors:<br \/>Candice Masse<br \/>astr partners<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EFKOaemoHGVG4pewXo1evDHZPCHSpq93pmXM6OhWC8dA8HdqDbqRUfOeDKyBFFdQZKUzvSS15UQdeV1cTBrgVYnRhwnEOevZM64Z0E59lqIP707xeeQWm9psrGKMa7SB\" rel=\"nofollow\" target=\"_blank\">candice.masse@astrpartners.com<\/a><\/p>\n<p>Media:<br \/>Chris Clark<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ERmwF5_KjtmpGg1qUOueYQ60cwAsNSlGqxCuImX7vTAVi8lAMHPrVTwI1u2G_RWcxQq7YDWp20U2D78iecLbRXWUIVXy66lkYM2X4r46ZN4=\" rel=\"nofollow\" target=\"_blank\">chris.clark@ocugen.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODMyOGRmY2EtMWEzZi00M2Y0LWJiZDMtODQ0NDY0MGQ0OWYxLTExOTYwNzMtMjAyNi0wOS0zMC1lbg==\/tiny\/Ocugen.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences. Euretina Innovation Spotlight (EIS) 2026 Location: VIECON, Vienna, AustriaDate: Wednesday, September 30, 2026Time: 2:34 p.m. CESTFormat: Company presentationTitle: Ocugen Company OverviewPresenter: Abhi Gupta, Executive Vice President, Commercial and Business Development, Ocugen 26th \u00a0Euretina Congress 2026 Location: VIECON, Vienna, AustriaDate: Thursday, October 1, 2026Time: 1:00\u20131:06 p.m. CESTFormat: Podium presentationTitle: Subretinal RORA-Based Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Phase 1\/2 Safety and Quantitative Lesion AnalysisPresenter: Jay Chhablani, MD Date: October 1\u20134, 2026Format: On-Demand ePosterTitle: Clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ocugen to Participate in Upcoming Scientific Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1006965","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ocugen to Participate in Upcoming Scientific Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocugen to Participate in Upcoming Scientific Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences. Euretina Innovation Spotlight (EIS) 2026 Location: VIECON, Vienna, AustriaDate: Wednesday, September 30, 2026Time: 2:34 p.m. CESTFormat: Company presentationTitle: Ocugen Company OverviewPresenter: Abhi Gupta, Executive Vice President, Commercial and Business Development, Ocugen 26th \u00a0Euretina Congress 2026 Location: VIECON, Vienna, AustriaDate: Thursday, October 1, 2026Time: 1:00\u20131:06 p.m. CESTFormat: Podium presentationTitle: Subretinal RORA-Based Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Phase 1\/2 Safety and Quantitative Lesion AnalysisPresenter: Jay Chhablani, MD Date: October 1\u20134, 2026Format: On-Demand ePosterTitle: Clinical &hellip; Continue reading &quot;Ocugen to Participate in Upcoming Scientific Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-30T11:26:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocugen to Participate in Upcoming Scientific Conferences\",\"datePublished\":\"2026-09-30T11:26:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/\"},\"wordCount\":618,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/\",\"name\":\"Ocugen to Participate in Upcoming Scientific Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=\",\"datePublished\":\"2026-09-30T11:26:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocugen-to-participate-in-upcoming-scientific-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocugen to Participate in Upcoming Scientific Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocugen to Participate in Upcoming Scientific Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ocugen to Participate in Upcoming Scientific Conferences - Market Newsdesk","og_description":"MALVERN, Pa., Sept. 30, 2026 (GLOBE NEWSWIRE) &#8212; Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming scientific conferences. Euretina Innovation Spotlight (EIS) 2026 Location: VIECON, Vienna, AustriaDate: Wednesday, September 30, 2026Time: 2:34 p.m. CESTFormat: Company presentationTitle: Ocugen Company OverviewPresenter: Abhi Gupta, Executive Vice President, Commercial and Business Development, Ocugen 26th \u00a0Euretina Congress 2026 Location: VIECON, Vienna, AustriaDate: Thursday, October 1, 2026Time: 1:00\u20131:06 p.m. CESTFormat: Podium presentationTitle: Subretinal RORA-Based Modifier Gene Therapy for Geographic Atrophy and Stargardt Disease: Phase 1\/2 Safety and Quantitative Lesion AnalysisPresenter: Jay Chhablani, MD Date: October 1\u20134, 2026Format: On-Demand ePosterTitle: Clinical &hellip; Continue reading \"Ocugen to Participate in Upcoming Scientific Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-30T11:26:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocugen to Participate in Upcoming Scientific Conferences","datePublished":"2026-09-30T11:26:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/"},"wordCount":618,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/","name":"Ocugen to Participate in Upcoming Scientific Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=","datePublished":"2026-09-30T11:26:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgzNjU2OSM3ODcwODYxIzIxODQ1MTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocugen-to-participate-in-upcoming-scientific-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocugen to Participate in Upcoming Scientific Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006965","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1006965"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1006965\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1006965"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1006965"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1006965"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}